SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA) Files An 8-K Other EventsItem 8.01Other Events.
On November 27, 2018, we sent a letter in response to two letters addressed to Sonoma Pharmaceuticals’ board of directors, publicly released by Montreux Equity Partners V, L.P. via EDGAR on a Schedule 13D on November 5, 2018 and November 20, 2018, in which Montreux requested, among others, that the board commence a review of strategic alternatives. The full text of the letter is furnished as Exhibit 99.1. The information furnished in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section.
This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to its future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s Annual Report on Form 10-K and in other documents that it files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.
Item 9.01Financial Statements and Exhibits.
| 99.1 | Letter by Sonoma Pharmaceuticals, Inc., dated November 27, 2018. |
Sonoma Pharmaceuticals, Inc. ExhibitEX-99.1 2 sonoma_8k-ex9901.htm LETTER BY SONOMA PHARMACEUTICALS Exhibit 99.1 Dan K. Turner,…To view the full exhibit click here
About SONOMA PHARMACEUTICALS, INC. (NASDAQ:SNOA)
Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.
